Developmental change and sexual difference in synaptic modulation produced by oxytocin in rat substantia gelatinosa neurons

We have previously reported that oxytocin produces an inward current at a holding potential of ?70 mV without a change in glutamatergic excitatory transmission in adult male rat spinal lamina II (substantia gelatinosa; SG) neurons that play a pivotal role in regulating nociceptive transmission. Oxytocin also enhanced GABAergic and glycinergic spontaneous inhibitory transmissions in a manner sensitive to a voltage-gated Na⁺-channel blocker tetrodotoxin. These actions were mediated by oxytocin-receptor activation. Such a result was different from that obtained by other investigators in young male rat superficial dorsal horn neurons in which an oxytocin-receptor agonist enhanced glutamatergic and GABAergic but not glycinergic spontaneous transmissions. In order to know a developmental change and also sexual difference in the actions of oxytocin, we examined its effect on spontaneous synaptic transmission in adult female and young male rat SG neurons by using the whole-cell patch-clamp technique in spinal cord slices. In adult female rats, oxytocin produced an inward current at ?70 mV without a change in excitatory transmission. GABAergic and glycinergic transmissions were enhanced by oxytocin, the duration of which enhancement was much shorter than in adult male rats. In young (11–21 postnatal days) male rats, oxytocin produced not only an inward but also outward current at ?70 mV, and presynaptically inhibited or facilitated excitatory transmission, depending on the neurons tested; both GABAergic and glycinergic transmissions were enhanced by oxytocin. The inhibitory transmission enhancements in adult female and young male rats were sensitive to tetrodotoxin. Although the data may not be enough to be estimated, it is suggested that synaptic modulation by oxytocin in SG neurons, i.e., cellular mechanism for its antinociceptive action, exhibits a developmental change and sexual difference.     

人工髋关节置换术发生股骨假体周围骨折的影响因素分析

目的:探讨人工髋关节置换术患者发生股骨假体周围骨折的相关危险因素,为临床预防和治疗提供参考资料。方法:回顾性分析2012年5月~2015年5月在我院接受人工髋关节置换术的92例患者的临床资料。根据是否发生股骨假体周围骨折将所选患者分为研究组和对照组,每组46例,比较两组患者的性别分布、年龄、骨折类型及假体固定方式等,分析影响患者发生股骨假体周围骨折的危险因素。结果:研究组患者骨折类型多为A2型,患者平均年龄、女性患者数及使用生物假体的比例均高于对照组,差异具有统计学意义(P0.05)。患者性别、年龄、骨折类型及假体固定方式是人工髋关节置换术患者发生股骨假体周围骨折的危险因素(OR=1.993、2.012和2.363,P0.05)。结论:高龄女性患者是发生股骨周围假体骨折的高危人群,骨质疏松及骨量减少是引发该并发症的主要危险因素。     

闭合复位与切开复位治疗桡骨远端骨折的疗效对比

目的:探讨闭合复位与切开复位对桡骨远端骨折患者的临床疗效。方法:回顾性分析2013年6月至2014年3月我院收治的60例桡骨远端骨折患者,随机数字表法分为切开复位组和闭合复位组,每组30例。闭合复位组患者给予闭合复位小夹板或石膏固定治疗,切开复位组患者给予切开复位内固定术治疗。观察并比较两组患者治疗前后掌倾角、尺偏角以及桡骨长度、术中出血量和手术时间,骨折愈合时间以及患者临床疗效进行检测并比较。结果:与治疗前相比,治疗后患者的掌倾角、尺偏角、桡骨长度水平均升高(P0.05);与闭合复位组相比,切开复位组患者掌倾角、尺偏角、桡骨长度评分水平较高(P0.05),术中出血量、手术时间水平较高(P0.05),临床治疗的优良率较高(P0.05),两组患者的骨折愈合时间无显著差异(P0.05)。结论:与闭合复位相比,切开复位能够明显恢复桡骨远端骨折患者的掌倾角、尺偏角以及桡骨长度,但手术时间以及术中出血量较多,临床疗效较好,两组患者的骨折愈合时间无明显差异。     

骨质疏松骨折与非骨质疏松骨折治疗比较

目的:对比骨质疏松骨折与非骨质疏松骨折的临床特点和治疗方式,为骨折的临床诊治提供依据。方法:选取2010年12月至2013年12月在我院接受治疗的骨折患者186例。根据骨质疏松情况,将所选患者分为骨质疏松骨折组和非骨质疏松骨折组,每组各93例。分析并比较两组患者的治病原因、治疗方法以及临床效果。结果:非骨质疏松骨折组患者交通事故和砸伤致伤率均显著高于骨质疏松骨折组,而跌倒伤致伤率低于骨质疏松骨折组,差异具有统计学意义(P0.05);两组患者手术治疗方式差异无统计学意义(P0.05);骨质疏松骨折组患者保守治疗的临床疗效优于非骨质疏松骨折组,差异具有统计学意义(P0.05);两组手术治疗的临床疗效比较,差异无统计学意义(P0.05)。结论:在临床治疗的实践中,应根据患者骨质疏松病情实施针对性的治疗,从而提升治疗的针对性和有效性。     

大鼠脊髓半横断伤联合架桥模型制作及评估

目的:建立大鼠脊髓半横断伤联合架桥模型,为研究脊髓损伤提供动物模型。方法:制作大鼠脊髓半横断伤模型,然后取大鼠前肢正中神经,并于半横断伤两端行正中神经架桥术。术后4周,左心室灌注固定取材,免疫组化染色检测GFAP、RECA、NF-200;另一部分动物行单宁酸-氯化铁灌注;观察移植物内有无血管、血管内有无血流、血管与周边神经纤维的关系。结果:外周神经架桥后4周,移植正中神经贴合于脊髓背侧1/2。移植神经内有RECA阳性的血管存在,而且有血流可以到达移植物内部,且神经纤维(NF-200阳性)与星形胶质细胞(GFAP阳性)关系紧密。结论:大鼠脊髓半横断伤联合正中神经架桥术后,由宿主可以向移植物内长入新生血管,血管有利于神经纤维的存活及生长。本模型为较好的外周神经移植的存活模型,可为进一步的深入研究提供一定的依据。     

镍钛形状记忆合金环抱器内固定术对多发性肋骨骨折患者术后疼痛、呼吸功能及肺部感染的影响

目的:探讨多发性肋骨骨折患者采用镍钛形状记忆合金环抱器内固定术治疗的临床效果。方法:选取2016年1月-2018年1月期间我院收治的97例多发性肋骨骨折患者。按照不同的治疗方法将患者分为对照组(n=47)和研究组(n=50),对照组患者给予胸部护板外固定术,研究组患者给予镍钛形状记忆合金环抱器内固定术。比较两组患者术后7 d的临床疗效,比较两组术前、术后7 d疼痛程度及呼吸功能情况,记录两组术后并发症发生情况。结果:研究组患者治疗后总有效率为92.00%(46/50),高于对照组患者的76.60%(36/47)(P0.05)。两组患者术后7 d视觉疼痛模拟评分量表(VAS)评分均较术前降低,且研究组低于对照组(P0.05)。两组患者术后7 d最大自主通气量占预计值百分比(MVV%)较术前升高,且研究组高于对照组(P0.05);两组患者术后7 d第1秒用力呼气肺活量占预计值百分比(FEV1%)比较无差异(P0.05)。研究组患者术后并发症总发生率8.00%(4/50),低于对照组的23.40%(11/47)(P0.05)。结论:多发性肋骨骨折经镍钛形状记忆合金环抱器内固定术治疗安全、有效,可明显减轻患者术后疼痛及改善呼吸功能,临床应用价值较高。     

基于PI3K/PTEN/AKT信号途径探讨褪黑素对脊髓损伤大鼠突触可塑性的影响

目的:探讨褪黑素对脊髓损伤大鼠突触可塑性的影响及磷脂酰肌醇3-激酶/张力蛋白同源基因/蛋白激酶B(PI3K/PTEN/AKT)信号途径在其中的作用。方法:选择4月龄SPF级雄性SD大鼠48只,将其随机分为对照组(CON)、模型组(SCI)、褪黑素组(MT)和褪黑素受体拮抗剂组(LUZ),每组12只大鼠。对照组大鼠背部切口后缝合,余下各组大鼠使用改良的Allen's法建立T9水平的脊髓损伤模型。模型建立后,褪黑素组及褪黑素受体拮抗剂组每天腹腔注射褪黑素及褪黑素抑制剂,剂量为12.5 mg·kg~(-1)·d~(-1),对照组和模型组每天注射同体积的生理盐水。治疗后第3、7、14、21、28天进行BBB评分,实验结束处死大鼠取胸椎8-10节段脊髓组织,分别采用免疫组化方法测尼氏小体数量及Western Blot检测PTEN、Synapsin、PSD-95、Gap-43、Akt蛋白的表达。结果:与SCI模型大鼠相比,MT给药干预14 d后的SCI大鼠BBB评分及痛觉压力值均明显降低(P0.05),尼氏小体灰度值提高(P 0.05),PTEN、Synapsin、PSD-95、Gap-43、Akt蛋白的表达均显著上调(P 0.05)。结论:MT可能通过激活PI3K/PTEN/Akt信号途径,上调突触可塑性相关蛋白的表达,促进SCI大鼠突触修复。     

舒芬太尼预处理对大鼠脊髓缺血再灌注损伤中炎性因子MPO，IL-6，IL-15的影响

目的:探讨舒芬太尼预处理对大鼠脊髓缺血再灌注损伤模型中炎性因子MPO,IL-6,IL-15的影响。方法:健康SD雄性大鼠30只,随机分为假手术组(Sham组,n=10);缺血再灌注组(IR组n=10);舒芬太尼预处理5μg/kg组(Suf5组,n=10)。采用动脉夹夹闭胸主动脉方法制备脊髓缺血再灌注模型。Tarlov法测大鼠运动评分,HE染色观察大鼠脊髓组织细胞形态,Western Blot法测脊髓组织中MPO的表达,ELISA法检测脊髓组织中IL-6,IL-15含量。结果:IR组Tarlov评分高于sham组,Suf5组Tarlov评分低于IR组。HE染色显微镜下见IR组脊髓组织内出现广泛的变性神经元,胞核固缩偏位碎裂,并有有空泡形成;Suf5组脊髓组织神经元损伤坏死数量减少,细胞核形态基本正常。Suf5组中MPO,IL-6,IL-15,含量均低于IR组,IR组中MPO,IL-6,IL-15含量均高于sham组,差异均有统计学意义(P0.05)。结论:舒芬太尼能降低大鼠脊髓缺血再灌注损伤组织中MPO,IL-15,1L-6表达,减轻炎症损害,进而减轻脊髓缺血再灌注损伤。     

Possible risk factors for keel bone damage in organic laying hens

Keel bone damage (KBD) in laying hens is an important welfare problem in both conventional and organic egg production systems. We aimed to identify possible risk factors for KBD in organic hens by analysing cross-sectional data of 107 flocks assessed in eight European countries. Due to partly missing data, the final multiple regression model was based on data from 50 flocks. Keel bone damage included fractures and/or deviations, and was recorded, alongside with other animal based measures, by palpation and visual inspection of at least 50 randomly collected hens per flock between 52 and 73 weeks of age. Management and housing data were obtained by interviews, inspection and by feed analysis. Keel bone damage flock prevalences ranged from 3% to 88%. Compiled on the basis of literature and practical experience, 26 potential associative factors of KBD went into an univariable selection by Spearman correlation analysis or Mann–Whitney U test (with P<0.1 level). The resulting nine factors were presented to stepwise forward linear regression modelling. Aviary v. floor systems, absence of natural daylight in the hen house, a higher proportion of underweight birds, as well as a higher laying performance were found to be significantly associated with a higher percentage of hens with KBD. The final model explained 32% of the variation in KBD between farms. The moderate explanatory value of the model underlines the multifactorial nature of KBD. Based on the results increased attention should be paid to an adequate housing design and lighting that allows the birds easy orientation and safe manoeuvring in the system. Furthermore, feeding management should aim at sufficient bird live weights that fulfil breeder weight standards. In order to achieve a better understanding of the relationships between laying performance, feed management and KBD further investigations are needed.     

Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model

Highly effective and safe drugs for the treatment of neuropathic pain are urgently required and it was shown that blocking T-type calcium channels can be a promising strategy for drug development for neuropathic pain. We have developed pyrrolidine-based T-type calcium channel inhibitors by structural hybridization and subsequent assessment of in vitro activities against Ca_v3.1 and Ca_v3.2 channels. Profiling of in vitro ADME properties of compounds was also carried out. The representative compound 17h showed comparable in vivo efficacy to gabapentin in the SNL model, which indicates T-type calcium channel inhibitors can be developed as effective therapeutics for neuropathic pain.